Carregant...
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both remission rates a...
Guardat en:
| Publicat a: | Front Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7675064/ https://ncbi.nlm.nih.gov/pubmed/33251134 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.562558 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|